600161 天坛生物
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,841,3745.59%5,180,4424,261,3054,112,1563,445,595
减:营业总成本1,680,642-5.80%3,429,7642,906,7942,873,2252,366,126
    其中:营业成本1,259,550-9.05%2,550,7212,170,0242,157,6871,743,664
               财务费用(23,691)9.36%(49,525)(57,989)(64,148)(30,304)
               资产减值损失180-203.94%(2,167)(2,254)(15,146)(917)
公允价值变动收益------------
投资收益23,05037.67%37,21328,12712,0001,153
    其中:对联营企业和合营企业的投资收益------------
营业利润1,191,56127.49%1,804,9951,432,1151,244,9071,104,537
利润总额1,190,36527.30%1,798,5981,426,2731,241,0181,104,872
减:所得税费用204,90827.39%289,140221,598172,204161,796
净利润985,45727.29%1,509,4591,204,6751,068,814943,077
减:非控股权益259,36925.06%399,570323,758308,802304,070
股东净利润726,08828.10%1,109,889880,916760,012639,007

市场价值指针
每股收益 (元) *0.37027.59%0.6700.5300.4700.510
每股派息 (元) *----0.1500.0500.1000.100
每股净资产 (元) *5.217-7.37%5.9615.3405.8643.602
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容